Vanda Pharmaceuticals Inc. (VNDA) Stock Rating Upgraded by Zacks Investment Research
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Wednesday.
According to Zacks, “Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It’s second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It’s third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. “
Several other equities research analysts also recently weighed in on the stock. HC Wainwright assumed coverage on shares of Vanda Pharmaceuticals in a report on Friday, May 26th. They issued a “buy” rating and a $18.00 price objective for the company. Jefferies Group LLC reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a report on Thursday, May 25th. TheStreet raised shares of Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Friday, May 12th. CIBC reissued an “outperform” rating and issued a $21.00 price target on shares of Vanda Pharmaceuticals in a report on Wednesday, April 12th. Finally, Oppenheimer Holdings, Inc. initiated coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, April 12th. They issued an “outperform” rating and a $21.00 price target for the company. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $20.78.
Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) remained flat at $13.90 during trading on Wednesday. 243,347 shares of the stock traded hands. The company’s 50-day moving average is $14.28 and its 200-day moving average is $14.54. The firm’s market cap is $619.27 million. Vanda Pharmaceuticals has a 52 week low of $10.40 and a 52 week high of $18.00.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.04. The company had revenue of $37.42 million during the quarter, compared to analyst estimates of $38.35 million. Vanda Pharmaceuticals had a negative return on equity of 10.42% and a negative net margin of 8.85%. Equities research analysts anticipate that Vanda Pharmaceuticals will post ($0.70) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Vanda Pharmaceuticals Inc. (VNDA) Stock Rating Upgraded by Zacks Investment Research” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/06/14/vanda-pharmaceuticals-inc-vnda-stock-rating-upgraded-by-zacks-investment-research.html.
A number of large investors have recently modified their holdings of VNDA. Russell Investments Group Ltd. bought a new stake in Vanda Pharmaceuticals during the fourth quarter valued at about $6,196,000. State Street Corp increased its stake in Vanda Pharmaceuticals by 27.2% in the fourth quarter. State Street Corp now owns 1,751,605 shares of the biopharmaceutical company’s stock valued at $27,935,000 after buying an additional 374,095 shares during the last quarter. Federated Investors Inc. PA increased its stake in Vanda Pharmaceuticals by 1,102.3% in the fourth quarter. Federated Investors Inc. PA now owns 70,961 shares of the biopharmaceutical company’s stock valued at $1,132,000 after buying an additional 65,059 shares during the last quarter. FMR LLC increased its stake in Vanda Pharmaceuticals by 928.0% in the fourth quarter. FMR LLC now owns 996,271 shares of the biopharmaceutical company’s stock valued at $15,891,000 after buying an additional 899,358 shares during the last quarter. Finally, Axiom International Investors LLC DE bought a new stake in Vanda Pharmaceuticals during the fourth quarter valued at about $2,357,000. 93.57% of the stock is owned by institutional investors.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.